索格列净在心血管疾病中的研究进展

Research progress of sotagliflozin in cardiovascular disease

索格列净(sotagliflozin)是一种对钠-葡萄糖协同转运蛋白(sodium-dependent glucose transporters,SGLT)1、2有双重抑制作用的药物,对SGLT1的抑制可抑制消化道葡萄糖和半乳糖的吸收,对SLGT2抑制则是减少肾小管对葡萄糖的重吸收,已被证明可有效治疗2型糖尿病(diabetes mellitus)。近年来,其在心血管疾病方面显示出巨大潜力。索格列净能降低2型糖尿病伴心血管危险因素患者的心血管不良事件。该文通过对近年来国内外索格列净对糖尿病合并心血管疾病应用的研究进行归纳总结,以期为索格列净在心血管方面的进一步应用提供指导。

Sotagliflozin is a drug with dual inhibitory effects on sodium-dependent glucose transporters(SGLT)1 and 2.Inhibition of SGLT1 can inhibit glucose and galactose absorption in the digestive tract,and inhibition of SLGT2 can reduce glucose reabsorption in the renal tubules.Sotagliflozin has been shown to be effective in the treatment of type 2 diabetes mellitus.In recent years,it has shown great potential in cardiovascular diseases.Soglitazone can reduce adverse cardiovascular events in type 2 diabetes patients with cardiovascular risk factors.This article summarized the research on the application of sotagliflozin in diabetes mellitus complicated with cardiovascular diseases at home and abroad in recent years,in order to provide guidance for the further application of sotagliflozin in cardiovascular diseases.